Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Aim(s): To describe the effect of LAN on NET biomarkers measured in CALM-NET.
Materials and methods: Adults with functional, well- or moderately-differentiated midgut NETs were treated with LAN 120 mg every 28 days for up to 52 weeks. Plasma and 24-h urinary 5-HIAA, chromogranin A (CgA) and neurokinin A (NKA) were measured and correlations between biomarkers assessed.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.